Agios Pharmaceuticals (AGIO)

Executive Summary

Agios Pharmaceuticals is a publicly traded biopharmaceutical company headquartered in Cambridge, MA, dedicated to developing differentiated small molecule therapies for rare genetic diseases and hematologic malignancies. The company's commercial success is anchored by mitapivat (Pyrukynd), an approved pyruvate kinase activator for pyruvate kinase deficiency (PKD) in adults, which has established a strong revenue base. Agios is now expanding the mitapivat franchise into pediatric PKD through two Phase 3 trials (ACTIVATE-KIDS) with data readouts expected in 2026-2027, representing a significant growth catalyst. Beyond PKD, the pipeline includes tebapivat (AG-946), a Phase 2 candidate for lower-risk myelodysplastic syndromes (MDS) and anemias, and AG-181, a Phase 1 phenylalanine ammonia lyase for phenylketonuria (PKU). With a solid balance sheet and a focused strategy on rare disease, Agios is positioned to drive long-term value through label expansion and pipeline progression. Key risks include competitive pressures and clinical trial execution, but near-term catalysts offer substantial upside.

Upcoming Catalysts (preview)

• Q3 2026Phase 3 pediatric PK deficiency data (ACTIVATE-KIDS)80% success
• Q1 2027Phase 2 tebapivat data in lower-risk MDS60% success
• Q4 2026Phase 1 AG-181 initial data in PKU70% success